|
|
Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC
Loic Ysebaert
,
Roch Houot
,
Ibrahim Yakoub-Agha
,
Franck Morschhauser
,
Charles Herbaux
et al.
Blood, 2015, 126 (23), pp.3979-3979
Journal articles
hal-01290424v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma Real World Evidence from the French Early Access Program
Roch Houot
,
Guillaume Manson
,
Jean-Baptiste Mear
,
Charles Herbaux
,
Jean Marc Schiano de Collela
et al.
Journal articles
hal-02076926v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA)
Guillaume Manson
,
Charles Herbaux
,
Jean Marc Schiano de Colella
,
René-Olivier Casasnovas
,
Aspasia Stamatoullas
et al.
Journal articles
hal-03665134v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
Franck Morschhauser
,
Nicolas Mounier
,
Catherine Sebban
,
Pauline Brice
,
Phillippe Solal-Celigny
et al.
Journal articles
hal-00744246v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
Guillaume Manson
,
Jean-Baptiste Mear
,
Charles Herbaux
,
Jean-Marc Schiano
,
Olivier Casasnovas
et al.
Journal articles
hal-02134578v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program
Aurore Perrot
,
Hélène Monjanel
,
Reda Bouabdallah
,
Philippe Quittet
,
Clémentine Sarkozy
et al.
Journal articles
hal-01259439v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Prolonged remissions after anti-PD1 discontinuation in patients with Hodgkin lymphoma
Guillaume Manson
,
Charles Herbaux
,
Pauline Brice
,
Krimo Bouabdallah
,
Aspasia Stamatoullas
et al.
Journal articles
hal-01812478v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies
Laurent Dercle
,
Fatima-Zohra Mokrane
,
Jean Marc Schiano de Colella
,
Apasia Stamatoullas
,
Franck Morschhauser
et al.
Journal articles
hal-02119287v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
Emmanuel Bachy
,
Roch Houot
,
Franck Morschhauser
,
Anne Sonet
,
Pauline Brice
et al.
Journal articles
hal-00933219v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts
Sarah Huet
,
Bruno Tesson
,
Jean-Philippe Jais
,
Andrew Feldman
,
Laura Magnano
et al.
Journal articles
hal-01788996v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
Guillaume Manson
,
Pauline Brice
,
Charles Herbaux
,
Kamal Bouabdallah
,
Chloé Antier
et al.
Journal articles
hal-02485796v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|